Chief Executive Officer Ph.D.,
Keats has an extensive range of experiences in founding and managing start-ups, research and development, and the delivering of high value commercial research programs as well as leading strategic and commercial transactions and projects. His work as delivered over $1B in commercial, research and investment funding and revenue.
Prior to Macrobiome Therapeutics, was Executive Director, Science Operations and Innovation Strategy as well as a founding Director at Samsara Eco, an innovative Australian biotech company creating commercial circularity through infinite plastic recycling catalysed by designed enzymes.
Previously, Keats has been Chief, Research & Innovation Services, and Director of the Office of Business Engagement and Commercialisation at the Australian National University; founder and CEO of Beta Therapeutics Pty. Ltd.; founder and Director of Phenomix Australia Pty. Ltd. and its parent, Phenomix Corporation (San Diego, USA); and Senior Scientist in Discovery Oncology at G.D. Searle, a Monsanto Company.
Keats was a Jane Coffin Childs post-doctoral fellow at the Laboratory of Immunology, National Institutes of Health (Bethesda, USA) and a Fulbright scholar at the MRC Laboratory of Molecular Biology (Cambridge, UK).